What's Happening?
Haleon, formerly known as GSK Consumer Healthcare, has announced a significant investment of Rs 2,000 crore to establish its first manufacturing facility in India and South Asia. This move is part of the UK firm's strategy to focus on high-growth markets,
following a recent investment in China. India, which is one of Haleon's fastest-growing markets and the world's second-largest oral health market, is expected to become one of the company's top three or four markets globally in the coming years. The new facility will be located in Pithampur, Madhya Pradesh, and is expected to be operational within the next two to three years. It aims to expand local production, enhance supply resilience, and support future growth. Currently, Haleon relies on third-party contract manufacturers for its products, which include Sensodyne, Crocin, and Eno.
Why It's Important?
The establishment of a manufacturing facility in India is a strategic move for Haleon, as it seeks to capitalize on the country's rapidly growing oral care market, valued at £1.8 billion. With Haleon holding over 70% of the market share, local manufacturing is seen as crucial for supporting its next phase of growth. This investment underscores the increasing importance of emerging markets, which contribute significantly to Haleon's overall business growth. The facility will not only boost local production but also enhance supply chain resilience, ensuring better service to the Indian market. This development is likely to have a positive impact on the local economy, creating jobs and fostering industrial growth in the region.
What's Next?
Haleon's global board is visiting India for the first time this week, reflecting the market's rising strategic importance. The company plans to focus on oral care, wellness brands like Eno and Centrum, and its OTC portfolio, including Crocin and Otrivin, over the next three to four years. These areas represent a multi-billion-pound market opportunity, where Haleon aims to capture significant market share and deliver strong double-digit compound annual growth rates (CAGR). The new facility is expected to play a key role in achieving these growth targets, supporting Haleon's expansion plans in India and South Asia.
